Connect Biopharma announced topline Phase 2 Seabreeze STAT data for rademikibart in COPD, showing large reductions in treatment failure, exacerbations, and ED visits. The company aims to align with the FDA on a Phase 3 registrational program and hosts an investor call; successful Phase 3 progression could unlock a significant upside via continued COPD advancement and Greater China licensing with Simcere.
Connect Biopharma released topline Phase 2 results for rademikibart in asthma. The primary endpoint missed statistical significance, although the therapy significantly improved a key lung function measure and had a favorable safety profile. With an upcoming Phase 2 COPD readout and FDA discussions on a Phase 3 plan, the stock faces near-term volatility and potential upside on clearer regulatory direction.
